This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

OKYO Pharma Dividendo

Dividendo criteri di controllo 0/6

Informazioni chiave

n/a

Rendimento del dividendo

n/a

Rapporto di remunerazione

Rendimento medio del settore	1.5%
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Utile per azione	-UK£0.26
Previsione del rendimento del dividendo	n/a

Aggiornamenti recenti sui dividendi

Nessun aggiornamento

Recent updates

Can OKYO Pharma (LON:OKYO) Afford To Invest In Growth?

Nov 26

Is OKYO Pharma (LON:OKYO) In A Good Position To Deliver On Growth Plans?

Jan 27

Here's Why We're Not At All Concerned With OKYO Pharma's (LON:OKYO) Cash Burn Situation

Sep 22

We Think OKYO Pharma (LON:OKYO) Can Easily Afford To Drive Business Growth

Mar 17

We're Interested To See How OKYO Pharma (LON:OKYO) Uses Its Cash Hoard To Grow

Dec 02

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Insufficient data to determine if OKYO's dividends per share have been stable in the past.

Dividendo in crescita: Insufficient data to determine if OKYO's dividend payments have been increasing.

Rendimento dei dividendi rispetto al mercato

OKYO Pharma Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di OKYO rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (OKYO)	n/a
Fondo del 25% del mercato (GB)	2.1%
Top 25% del mercato (GB)	5.7%
Media del settore (Biotechs)	1.5%
Analista previsionale (OKYO) (fino a 3 anni)	n/a

Dividendo notevole: Unable to evaluate OKYO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Dividendo elevato: Unable to evaluate OKYO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Distribuzione degli utili agli azionisti

Copertura degli utili: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Unable to calculate sustainability of dividends as OKYO has not reported any payouts.

This company listing is no longer active

OKYO Pharma Dividendo

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sui dividendi

Recent updates

OKYO Pharma Announces Change of Delisting Date to 22 May 2023

OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease

Can OKYO Pharma (LON:OKYO) Afford To Invest In Growth?

OKYO Pharma Limited Announces U.S. IND Filing on Ok-101 for the Treatment of Dry Eye Disease

High number of new and inexperienced directors

High number of new and inexperienced directors

OKYO Pharma Plans Fourth Quarter 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm

OKYO Pharma Limited, Annual General Meeting, Sep 07, 2022

OKYO Pharma Limited announced delayed 20-F filing

High number of new and inexperienced directors

OKYO Pharma Limited Announces Successful Completion of A Pre-IND Meeting with the U.S. Food and Drug Administration on the Development of OK-101 to Treat Dry Eye Disease

Is OKYO Pharma (LON:OKYO) In A Good Position To Deliver On Growth Plans?

OKYO Pharma Limited Announces First-in-Class Drug Candidate OK-101 Displaying Both Anti-inflammatory and Ocular Pain-Reducing Potential to Treat Dry Eye Disease

Here's Why We're Not At All Concerned With OKYO Pharma's (LON:OKYO) Cash Burn Situation

Independent Non-Executive Director Kunwar Shailubhai has left the company

OKYO Pharma Announces Positive Data and Results in an Animal Model Using Topically Administered OK-201 to Treat Neuropathic Ocular Pain

We Think OKYO Pharma (LON:OKYO) Can Easily Afford To Drive Business Growth

OKYO Pharma Limited Has U.S. Patent Issues Covering its Lipid Conjugated Peptide Analogues for Treating Ocular Pain and Inflammation

Okyo Pharma Limited Announces Filing of A Patent Application Covering the Use of Chemerin and Associated Analogues to Treat “Cytokine Storm” Associated with COVID-19 and ARDS

OKYO Pharma Limited Appoints Gary S. Jacob as Chief Executive Officer

We're Interested To See How OKYO Pharma (LON:OKYO) Uses Its Cash Hoard To Grow

OKYO Pharma Limited announced that it has received £5.437104 million in funding

Stabilità e crescita dei pagamenti

Rendimento dei dividendi rispetto al mercato

Distribuzione degli utili agli azionisti

Pagamenti in contanti agli azionisti

Scoprire le società che pagano dividendi forti